Novartis India Limited
₹1,880.80▼ -59.30 (-3.06%)
NOVARTIND·NSE·Healthcare
Market Cap
4692.86 Cr
PE Ratio
49.84
Volume
31,498
Day High - Low
1949.10 - 1850.00
52W High-Low
2588.80 - 672.25
₹1,880.80▼ -59.30 (-3.06%)
Market Cap4692.86 Cr
PE Ratio49.84
Volume31,498
Day High - Low1949.10 - 1850.00
52W High-Low2588.80 - 672.25
Novartis India Limited (NOVARTIND): company summary
The company's annual revenue fell 0.5% year-over-year, while its latest quarter revenue rose 18.2% compared to the same quarter a year earlier.
Novartis India Limited (NOVARTIND) is a micro-cap Healthcare company valued at ₹4,693 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Novartis India Limited last traded at ₹1,880.8, down 3.06% on the day.
- Recent developments
- On 2026-09-09, Novartis India Ltd announced a major brand acquisition deal with Pfizer Inc to acquire trademarks and intellectual property rights for ₹1,250 crore, which contributed to a 20% jump in its stock price. On 2026-09-07, the company confirmed the acquisition of BP drug trademarks from Pfizer Inc as part of the same deal. On 2026-07-30, the company reported standalone net sales of ₹103.81 crore for the quarter ended June 2026, up 18.57% year-over-year.
- Financial performance
- The company's annual revenue fell 0.5% year-over-year, while its latest quarter revenue rose 18.2% compared to the same quarter a year earlier. Net profit declined 7.7% annually but increased 14.3% in the latest quarter. The net profit margin narrowed 2.1 percentage points to 26.3%, and return on equity remained at 11.4%.
- Valuation multiples
- The stock trades at 49.8 times earnings, a premium to the Healthcare median of 32.0, 7.32 times book value. It yields 1.0%.
- Things to watch
- The company's annual net profit fell 7.7% year-over-year, and the net profit margin declined 2.1 percentage points to 26.3%. The stock is 24.1% below its 52-week high, and the company's revenue has declined 2.2% annually over the past three years.
- Where it stands
- The company's latest quarter revenue and net profit both rose compared to the same quarter a year earlier, but annual revenue and net profit declined. The stock is 24.1% below its 52-week high, and the net profit margin narrowed 2.1 percentage points to 26.3%. The company's recent acquisition of trademarks from Pfizer Inc may signal a shift in its business strategy.
Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.5/10
Fair
Fair Value
Sign in to see
ROE
11.38%
Average
P/E
49.84x
Expensive
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹1850
₹1949
52W₹672.25
₹2589
DocStoX take
Supported by risk (8.0) and momentum (6.9), but held back by valuation (0.0). Risk looks strong at 8.0, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence5.5
/10
Fair
Quality
Solid
ROE 11.4%
Valuation
Expensive
P/E 49.8×
Growth
Steady
Revenue -1.4% 5Y CAGR
Risk
Low risk
D/E 0.00
Momentum
Firm
63% of 52-week range
At a glance
Market Cap
₹4,693 Cr
52W High / Low
₹2589 / ₹672
Dividend Yield
1.03%
Promoter Holding
70.68%
EPS (TTM)
₹37.74
Book Value
₹331.54
Key highlights
- Profit compounding 35% a year
- Low leverage — D/E 0.00
- Healthy net margin (26%)
- Revenue shrinking 1% a year
- Valuation is weak (0.0/10)
3 Positives2 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Novartis India Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Novartis India Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Novartis India Limited with peers
Novartis India Limited vs Sun Pharmaceutical Industries LimitedNovartis India Limited vs Divi's Laboratories LimitedNovartis India Limited vs Torrent Pharmaceuticals LimitedNovartis India Limited vs Apollo Hospitals Enterprise LimitedNovartis India Limited vs Zydus Lifesciences LimitedNovartis India Limited vs Laurus Labs Limited
Related tools & concepts
Value Novartis India Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing